Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation

Bone Marrow Transplantation

Volumn 27, Issue 3, 2001, Pages 287-293

  Solano, C ^a   Badia, B ^a   Lluch, A ^a   Marugan, I ^a   Benet, I ^a   Arbona, C ^a   Prosper, F ^a   Garcia Conde J ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Apheresis tumor cell contamination; High risk breast cancer; PBSC transplant

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOKERATIN; EPIRUBICIN; ETOPOSIDE; FLUCONAZOLE; FLUOROURACIL; MELPHALAN; NORFLOXACIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; THIOTEPA;

ADULT; APHERESIS; ARTICLE; AXILLARY LYMPH NODE; BREAST ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTAMINATION; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TUMOR CELL;

ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; BREAST NEOPLASMS; CELL SEPARATION; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT FAILURE; TUMOR STEM CELLS;

EID: 0035109520     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702782     Document Type: Article

References (53)

1. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer
2. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer
3. High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer
4. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: A role for peripheral blood progenitor transplant
5. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: An effective consolidation chemotherapy regimen for early metastatic breast cancer
6. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results
7. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
8. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes
9. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: A practical approach
10. Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer
11. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes
12. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): 9082/SWOG 9114/NCIC MA-13
13. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy
14. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes
15. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases
16. Tumor cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up
17. Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis
18. Outcome of primary-breast cancer patients with micrometastases: A long-term follow-up study
19. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer
20. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support
21. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer
22. High-dose chemotherapy in patients with breast cancer: Evaluation of infusing peripheral blood stem cells containing occult tumor cells
23. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic transplantation
24. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients
25. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy
26. 132 epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: The ISOBM TD5-1 Workshop
27. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. Establishment of objective criteria for the evaluation of immunostained cells
28. Nonparametric estimation from incomplete observations
29. Preclinical studies and clinical correlation of the effect of alkylating dose
30. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer
31. The importance of dose intensity in chemotherapy of metastatic breast cancer
32. Survival after first recurrence of breast cancer. The Miami experience
33. Prognostic factors in inflammatory breast cancer and therapeutic implications
34. Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: The role of induction chemotherapy
35. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer
36. Tumor cell contamination of bone marrow harvest products: Clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy
37. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: Prognostic indicators of progression-free and overall survival
38. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer
39. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant
40. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques
41. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
42. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
43. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
44. Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer
45. Combined positive/negative purging and transplantation of peripheral blood progenitor cell autografts in breast cancer patients: A pilot study
46. Minimal residual disease in solid tumor malignancies: A review
47. Clinical significance of bone marrow metastases in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation
48. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and transcriptase-polymerase chain reaction
49. Detection and clinical significance of minimal tumor cell contamination of peripheral stem cell harvests
50. Sensitive detection of occult breast cancer by reverse-transcriptase polymerase chain reaction
51. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients
52. Annual hazard rates of recurrence for breast cancer after primary therapy
53. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America